TrialFuture oncology (London, England)2026

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.

Matthew D Galsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.